



## Several presentations demonstrate the benefits of biotherapy monitoring at ECCO meeting

### ***Additional scientific validation of the Lisa-Tracker theranostics approach***

**Croissy-Beaubourg**, February 26, 2014 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and *in vitro* diagnostics, is proud to announce that several publications sustaining the relevance of dosage and monitoring of anti-TNF $\alpha$  therapies were presented at the 9<sup>th</sup> meeting of ECCO (European Crohn's and Colitis Organization) in Copenhagen, the annual European meeting on Inflammatory Bowel Disease (IBD). These studies lend validation to Theradiag's theranostics approach with the Lisa-Tracker, the first CE marked assay portfolio allowing simultaneous dosage of the prescribed anti-TNF $\alpha$  and antibodies directed against the medication (ADAb).

*« These studies show the current and future benefits of testing anti-drug antibodies (ADAb) and corresponding treatment levels as part of patient care, from the initial phase of treatment to the maintenance and remission phases. For these phases, information regarding anti-TNF $\alpha$  and corresponding ADAb levels allow us to adapt the dosage, and provide information on the appropriate therapeutic strategy to adopt in the cases of treatment resistance »,* comments Pr. Jean-Christophe Saurin, M.D., Ph.D., Hepatologist and Gastroenterologist, HCL University Hospital in Lyon.

Two abstracts demonstrated the relevance of ADAb dosage in predicting response to treatment with infliximab (Remicade<sup>®</sup>) and adalimumab (Humira<sup>®</sup>).

A first prospective study<sup>1</sup>, conducted on a cohort of 93 patients by Dr. Manon Leclerc, M.D., Saint Etienne University Hospital, showed that lasting levels of anti-infliximab antibodies (present in two consecutive samples) are strongly associated with loss of response to infliximab. Dosage of these ADAb allows clinicians to choose the treatment most suited to the individual need of the patient.

A second prospective study<sup>2</sup> conducted by Pr. Xavier Roblin, M.D., Ph.D., Saint Etienne University Hospital on an 82-patients cohort demonstrated that drug and ADAb levels monitoring in the cases of treatment resistance is useful for adapting the treatment strategy (optimization or switch).

*“The growing interest of auto-immune and inflammatory disease specialists for biotherapy monitoring lends validation once again to our theranostics approach. This is an important step towards more personalized medicine. Our Lisa-Tracker kits allow for simultaneous dosage of prescribed anti-TNF $\alpha$  therapy and corresponding anti-drug antibodies. They are now routinely used in many national and international hospitals”,* concludes Michel Finance, CEO of Theradiag.

---

<sup>1</sup> European Crohn's and Colitis Organization (ECCO) 2014, February 20-22, Copenhagen. Poster 387

<sup>2</sup> European Crohn's and Colitis Organization (ECCO) 2014, February 20-22, Copenhagen. Digital Oral Poster 056



### **About Theradiag**

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is also developing new diagnostics biomarkers thanks to its microRNA platform, in order to diagnose and monitor HIV/AIDS and rectal cancer. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 55 employees.

For more information about Theradiag, please visit our website: [www.theradiag.com](http://www.theradiag.com)



#### **Theradiag**

Relations investisseurs

**Nathalie Trepo**

Tél: 01 64 62 10 12

[ntrepo@theradiag.com](mailto:ntrepo@theradiag.com)

#### **NewCap.**

Communication financière  
et Relations Investisseurs

**Valentine Brouhot /**

**Pierre Laurent**

Tél. : 01 44 71 94 94

[theradiag@newcap.fr](mailto:theradiag@newcap.fr)

#### **Alize RP**

Relations Presse

**Caroline Carmagnol**

[caroline@alizerp.com](mailto:caroline@alizerp.com)

Tél. : 06 64 18 99 59